Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Colony stimulating factor receptor

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    24 result(s) found for: Colony stimulating factor receptor. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-001724-35 Sponsor Protocol Number: AMASCIS-02 Start Date*: 2020-06-16
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Paz (FIBHULP)
    Full Title: AMASCIS-02. ALOGENIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS IN ISCHEMIC STROKE. A PHASE IIB MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL.
    Medical condition: Moderate-severe ischemic stroke
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004852 10055221 Ischemic stroke LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002961-23 Sponsor Protocol Number: ODO-TE-B301 Start Date*: Information not available in EudraCT
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally...
    Medical condition: Patients with Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) HU (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) AT (Prematurely Ended) DE (Completed) BE (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-000547-17 Sponsor Protocol Number: FPA008-002 Start Date*: 2015-11-18
    Sponsor Name:Five Prime Therapeutics, Inc.
    Full Title: A Phase 1/2 Study of FPA008, an anti-CSF1 Receptor Antibody, in Patients with Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)
    Medical condition: Pigmented villonodular synovitis (PVNS)/Diffuse Type Tenosynovial Giant Cell Tumor (dt-TGCT)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10047413 Villonodular synovitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003243-21 Sponsor Protocol Number: XL092-303 Start Date*: 2022-10-06
    Sponsor Name:Exelixis, Inc.
    Full Title: A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
    Medical condition: Metastatic colorectal cancer (CRC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003907-20 Sponsor Protocol Number: C16051 Start Date*: 2019-07-10
    Sponsor Name:Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical Company Limit
    Full Title: Open-Label Phase 1 Study to Assess the Maximum Tolerated Dose, Pharmacokinetics, and Safety of Ixazomib Administered Intravenously to Pediatric Patients Aged 0 to <18 Years With Relapsed or Refract...
    Medical condition: Relapsed or Refractory Acute Lymphoblastic Leukemia and Relapsed or Refractory Lymphoblastic Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001379-18 Sponsor Protocol Number: QEL-001-CLN-01 Start Date*: 2023-07-07
    Sponsor Name:Quell Therapeutics Limited
    Full Title: A single-arm, open-label, multi-centre, phase I/II study evaluating the safety and clinical activity of QEL-001, an autologous CAR T regulatory cell treatment targeting HLA-A2, in HLA-A2/ A28neg pa...
    Medical condition: Prevention of liver transplant rejection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10024715 Liver transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005219-98 Sponsor Protocol Number: PH3-01 Start Date*: 2012-10-08
    Sponsor Name:Galena Biopharma, Inc
    Full Title: Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)
    Medical condition: Operable early-stage, node-positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10071113 Node-positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BG (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-002189-34 Sponsor Protocol Number: HLX11-BC301 Start Date*: 2022-10-26
    Sponsor Name:Shanghai Henlius Biotech, Inc.
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Pertuzumab Biosimilar HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy o...
    Medical condition: HER2-Positive and HR-Negative Early-stage or Locally advanced Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10083232 HER2 negative breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) BG (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003896-37 Sponsor Protocol Number: ODO-TE-B201 Start Date*: 2019-06-18
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multinational, Multicenter, Phase 2 Study of Tesetaxel plus a Reduced Dose of Capecitabine in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer ...
    Medical condition: breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-002364-27 Sponsor Protocol Number: ABCSG_52 Start Date*: 2020-04-09
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: An open-label, two-arm, randomized, single-stage phase II study of ATezolizumab in combination with dual HER2 blockade plus epirubicin as NEoadjuvant therapy for HER2-positive early breast cancer
    Medical condition: HER2-positive early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-000907-19 Sponsor Protocol Number: ML29755 Start Date*: 2015-09-10
    Sponsor Name:University Medical Center Groningen
    Full Title: MPDL3280A treatment in patients with locally advanced or metastatic solid tumors after or during investigational imaging
    Medical condition: solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004715-41 Sponsor Protocol Number: ODO-TE-B202 Start Date*: 2019-12-24
    Sponsor Name:Odonate Therapeutics, Inc.
    Full Title: A Multicenter, Phase 2 Study of Tesetaxel plus Three Different PD-(L)1 Inhibitors in Patients with Triple-Negative, Locally Advanced or Metastatic Breast Cancer and Tesetaxel Monotherapy in Elderly...
    Medical condition: Breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006201 Breast cancer stage III PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006202 Breast cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005923-35 Sponsor Protocol Number: RVU120-SOL-021 Start Date*: 2021-05-21
    Sponsor Name:Ryvu Therapeutics S.A.
    Full Title: An Open-label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapsed / Refractory Metastatic or Advanced Solid Tumors
    Medical condition: Relapsed / Refractory Metastatic or Advanced Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003277-42 Sponsor Protocol Number: MCLA-128-CL01 Start Date*: 2015-01-13
    Sponsor Name:Merus B.V.
    Full Title: A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors
    Medical condition: Solid Tumors
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10049280 Solid tumour LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Ongoing) FR (Trial now transitioned) PT (Completed) NO (Trial now transitioned) DE (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-000977-62 Sponsor Protocol Number: 012418QM Start Date*: 2018-09-28
    Sponsor Name:Queen Mary University of London
    Full Title: BARBICAN: A randomised, open-label Phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer
    Medical condition: Triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000348-11 Sponsor Protocol Number: EC-FV-06 Start Date*: 2011-11-14
    Sponsor Name:Endocyte, Inc.
    Full Title: A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL COMPARING VINTAFOLIDE (EC145) AND PEGYLATED LIPOSOMAL DOXORUBICIN (PLD/DOXIL®/CAELYX®) IN COMBINATION VERSUS PLD IN PARTICIPANTS WITH PLATINUM-RESISTANT OVAR...
    Medical condition: Platinum Resistant Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Prematurely Ended) ES (Completed) BE (Prematurely Ended) PL (Prematurely Ended) HU (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001648-24 Sponsor Protocol Number: MedOPP321_ABIGAIL Start Date*: 2021-06-23
    Sponsor Name:MEDICA SCIENTIA INNOVATION RESEARCH S.L.
    Full Title: randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a short course of induction chemotherapy with paclitaxel as f...
    Medical condition: Previously untreated unresectable locally advanced or metastatic hormone receptor (HR)-positive/ human epidermal growth factor receptor 2 (HER2)-negative breast cancer with aggressive disease crite...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003592-34 Sponsor Protocol Number: IMGN853-0419 Start Date*: 2021-12-21
    Sponsor Name:ImmunoGen, Inc.
    Full Title: PICCOLO: A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Rece...
    Medical condition: Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061269 Malignant peritoneal neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) BE (Completed) FR (Completed) IT (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002549-39 Sponsor Protocol Number: Ponatinib-1501 Start Date*: 2020-12-07
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Pivotal Phase 1/2, Single-Arm, Open-label Study to Evaluate the Safety and Efficacy of Ponatinib With Chemotherapy in Pediatric Patients With Philadelphia Chromosome-Positive (Ph+) Acute Lympho...
    Medical condition: acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed) CZ (Completed) NL (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) PT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-000444-26 Sponsor Protocol Number: 17-BI-1206-02 Start Date*: 2018-05-02
    Sponsor Name:BioInvent International AB
    Full Title: Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractor...
    Medical condition: Indolent B-Cell Non-Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Ongoing) PL (Prematurely Ended) DE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 08 15:44:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA